Update on calciphylaxis etiopathogenesis, diagnosis, and management.

Calciphylaxis is a rare painful skin condition classically seen in patients with end-stage renal disease (ESRD), particularly those on chronic dialysis; however, it also has been increasingly reported in patients with normal renal function. Calciphylaxis is associated with high mortality rates, and excruciating pain and nonhealing ulcers often lead to recurrent hospitalizations and infectious complications. It is critical for dermatologists to recognize the clinical features of calciphylaxis to ensure accurate and timely diagnosis and proper management. In this article, we provide an update on calciphylaxis etiopathogenesis, diagnosis, and management, and we highlight the challenges faced in managing this potentially fatal condition.

[1]  R. Thadhani,et al.  Calciphylaxis in Patients With Normal Renal Function: A Case Series and Systematic Review , 2018, Mayo Clinic proceedings.

[2]  J. Buades,et al.  SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels , 2018, Journal of Nephrology.

[3]  P. Senet,et al.  Calciphylaxis in haemodialysed patients: diagnostic value of calcifications in cutaneous biopsy , 2018, The British journal of dermatology.

[4]  D. Christiadi,et al.  Calciphylaxis in a dialysis patient successfully treated with high-dose vitamin K supplementation , 2017, Clinical kidney journal.

[5]  J. Strand,et al.  Underreported use of palliative care and patient‐reported outcome measures to address reduced quality of life in patients with calciphylaxis: a systematic review , 2017, The British journal of dermatology.

[6]  C. Lohse,et al.  Histopathology of Calciphylaxis: Cohort Study With Clinical Correlations , 2017, The American Journal of dermatopathology.

[7]  S. Booth,et al.  Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis. , 2017, Journal of the American Society of Nephrology : JASN.

[8]  J. Floege,et al.  Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  C. Rabito,et al.  The Role of Bone Scintigraphy in the Diagnosis of Calciphylaxis , 2017, JAMA dermatology.

[10]  A. Weaver,et al.  Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis. , 2016, Mayo Clinic proceedings.

[11]  R. Thadhani,et al.  Calciphylaxis in peritoneal dialysis patients: a single center cohort study , 2016, International journal of nephrology and renovascular disease.

[12]  R. Nair,et al.  Advanced-stage calciphylaxis: Think before you punch , 2016, Cleveland Clinic Journal of Medicine.

[13]  R. Thadhani,et al.  A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors. , 2016, Journal of the American Society of Nephrology : JASN.

[14]  A. Dominguez,et al.  Calciphylaxis: Controversies in Pathogenesis, Diagnosis and Treatment , 2016, The American journal of the medical sciences.

[15]  Janet M. Davis The Relationship Between Obesity and Calciphylaxis: A Review of the Literature. , 2016, Ostomy/Wound Management.

[16]  P. Nagpal,et al.  Gastrointestinal Bleeding Secondary to Calciphylaxis , 2015, The American journal of case reports.

[17]  S. Nigwekar,et al.  Multidisciplinary approach to calcific uremic arteriolopathy , 2015, Current opinion in nephrology and hypertension.

[18]  M. Kamdar,et al.  Calciphylaxis: risk factors, diagnosis, and treatment. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  C. Vermeer,et al.  Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  N. Chen,et al.  Adipocyte induced arterial calcification is prevented with sodium thiosulfate. , 2014, Biochemical and biophysical research communications.

[21]  B. Astor,et al.  Pilot Study of the Effect of Lanthanum Carbonate (Fosrenol®) In Patients with Calciphylaxis: A Wisconsin Network for Health Research (WiNHR) Study , 2014, Journal of nephrology & therapeutics.

[22]  C. Chao,et al.  Tumoral calcinosis in renal failure. , 2014, QJM : monthly journal of the Association of Physicians.

[23]  M. Hoang,et al.  Cutaneous Calciphylaxis: A Retrospective Histopathologic Evaluation , 2013, The American Journal of dermatopathology.

[24]  K. Mahaffey,et al.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. , 2012, The New England journal of medicine.

[25]  R. Weenig,et al.  Net-like pattern of calcification on plain soft-tissue radiographs in patients with calciphylaxis. , 2012, Journal of the American Academy of Dermatology.

[26]  A. Fine,et al.  Calciphylaxis: The Beginning of the End? , 2008, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[27]  M. Pittelkow,et al.  Calciphylaxis: natural history, risk factor analysis, and outcome. , 2007, Journal of the American Academy of Dermatology.

[28]  P. Coates,et al.  VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Calcific Uremic Arteriolopathy: Advances in Pathogenesis and Treatment , 2007 .

[29]  M. Ashby,et al.  Symptomatic management of calciphylaxis: a case series and review of the literature. , 2006, Journal of pain and symptom management.

[30]  D. Spector,et al.  Successful treatment of calciphylaxis with intravenous sodium thiosulfate. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  J. Dear,et al.  Calciphylaxis , 2003, The Lancet.

[32]  A. Schwarz,et al.  The serum protein α2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification , 2003 .

[33]  A. Fine,et al.  Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. , 2002, Kidney international.

[34]  A. Evan,et al.  Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  W. White,et al.  A case control study of proximal calciphylaxis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  R. Behringer,et al.  Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein , 1997, Nature.

[37]  G. Burg,et al.  Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. , 1995, Journal of the American Academy of Dermatology.

[38]  C. Edelstein,et al.  Systemic calciphylaxis presenting as a painful, proximal myopathy. , 1992, Postgraduate medical journal.